loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
.
..
.
.
.
"we had (borrelia miyamotoi) as the new disease for the physicians to be aware of", told rusk....
�such figures underline how vital it is that the government supports the nhs to improve waiting times this year.�.